These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24503251)

  • 1. Non-invasive in vivo characterization of microclimate pH inside in situ forming PLGA implants using multispectral fluorescence imaging.
    Schädlich A; Kempe S; Mäder K
    J Control Release; 2014 Apr; 179():52-62. PubMed ID: 24503251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping microclimate pH distribution inside protein-encapsulated PLGA microspheres using confocal laser scanning microscopy.
    Liu Y; Schwendeman SP
    Mol Pharm; 2012 May; 9(5):1342-50. PubMed ID: 22428586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
    Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
    J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping in vivo microclimate pH distribution in exenatide-encapsulated PLGA microspheres.
    Hong JKY; Schutzman R; Olsen K; Chandrashekar A; Schwendeman SP
    J Control Release; 2022 Dec; 352():438-449. PubMed ID: 36030989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of microclimate pH in poly(lactic-co-glycolic acid) films.
    Ding AG; Shenderova A; Schwendeman SP
    J Am Chem Soc; 2006 Apr; 128(16):5384-90. PubMed ID: 16620110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process.
    Kempe S; Metz H; Mäder K
    J Control Release; 2008 Sep; 130(3):220-5. PubMed ID: 18611421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability.
    Schoenhammer K; Petersen H; Guethlein F; Goepferich A
    Int J Pharm; 2009 Apr; 371(1-2):33-9. PubMed ID: 19135512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopy.
    Kempe S; Metz H; Pereira PG; Mäder K
    Eur J Pharm Biopharm; 2010 Jan; 74(1):102-8. PubMed ID: 19545625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-situ forming PLGA implants for intraocular dexamethasone delivery.
    Bode C; Kranz H; Siepmann F; Siepmann J
    Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The microclimate pH in poly(D,L-lactide-co-hydroxymethyl glycolide) microspheres during biodegradation.
    Liu Y; Ghassemi AH; Hennink WE; Schwendeman SP
    Biomaterials; 2012 Oct; 33(30):7584-93. PubMed ID: 22819499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
    Kranz H; Bodmeier R
    Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving release completeness from PLGA-based implants for the acid-labile model protein ovalbumin.
    Duque L; Körber M; Bodmeier R
    Int J Pharm; 2018 Mar; 538(1-2):139-146. PubMed ID: 29355654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-situ forming composite implants for periodontitis treatment: How the formulation determines system performance.
    Do MP; Neut C; Metz H; Delcourt E; Mäder K; Siepmann J; Siepmann F
    Int J Pharm; 2015; 486(1-2):38-51. PubMed ID: 25791762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
    Kranz H; Bodmeier R
    Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of injection site on in situ implant formation and drug release in vivo.
    Patel RB; Solorio L; Wu H; Krupka T; Exner AA
    J Control Release; 2010 Nov; 147(3):350-8. PubMed ID: 20728486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ forming implants for the delivery of metronidazole to periodontal pockets: formulation and drug release studies.
    Kilicarslan M; Koerber M; Bodmeier R
    Drug Dev Ind Pharm; 2014 May; 40(5):619-24. PubMed ID: 24369747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of process and formulation parameters on characteristics and internal morphology of poly(d,l-lactide-co-glycolide) microspheres formed by the solvent evaporation method.
    Mao S; Shi Y; Li L; Xu J; Schaper A; Kissel T
    Eur J Pharm Biopharm; 2008 Feb; 68(2):214-23. PubMed ID: 17651954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A starch-based implant as a controlled drug release system: Non-invasive in vivo characterization using multispectral fluorescence imaging.
    Esfahani G; Lucas H; Syrowatka F; Mäder K
    J Control Release; 2023 Jun; 358():358-367. PubMed ID: 37156301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.
    Solorio L; Olear AM; Hamilton JI; Patel RB; Beiswenger AC; Wallace JE; Zhou H; Exner AA
    Theranostics; 2012; 2(11):1064-77. PubMed ID: 23227123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide.
    Wischke C; Zhang Y; Mittal S; Schwendeman SP
    Pharm Res; 2010 Oct; 27(10):2063-74. PubMed ID: 20668921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.